基础胰岛素与胰高血糖素样肽-1受体激动剂联合使用
Basal Insulin Use With GLP-1 Receptor Agonists.
作者信息
Anderson Sarah L, Trujillo Jennifer M
机构信息
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
出版信息
Diabetes Spectr. 2016 Aug;29(3):152-60. doi: 10.2337/diaspect.29.3.152.
Abstract
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain with the combination, which provides a safe and effective alternative to basal-bolus insulin with less treatment burden. Fixed-ratio combination products that administer both agents in a single injection are in the pipeline and will offer additional options for clinicians and patients. This review focuses on the rationale for, clinical evidence on, and implications of using this combination of therapies in the treatment of type 2 diabetes.
摘要
简而言之，基础胰岛素与胰高血糖素样肽-1受体激动剂联合使用的情况越来越普遍，为2型糖尿病患者带来了诸多潜在益处。临床研究表明，这种联合用药可改善血糖控制，降低低血糖风险和体重增加风险，是一种安全有效的替代基础-餐时胰岛素治疗的方法，且治疗负担较轻。将两种药物单次注射给药的固定比例复方产品正在研发中，将为临床医生和患者提供更多选择。本综述重点关注这种联合疗法在2型糖尿病治疗中的理论依据、临床证据及意义。
相似文献
1
Basal Insulin Use With GLP-1 Receptor Agonists.
Diabetes Spectr. 2016 Aug;29(3):152-60. doi: 10.2337/diaspect.29.3.152.
2
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27.
3
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18.
4
Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
Curr Med Res Opin. 2018 Jan;34(1):1-10. doi: 10.1080/03007995.2017.1372118. Epub 2017 Sep 28.
5
GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Pharmacotherapy. 2014 Nov;34(11):1174-86. doi: 10.1002/phar.1507.
6
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.
Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. doi: 10.1586/17446651.2016.1113129. Epub 2015 Nov 18.
7
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.
Curr Diab Rep. 2017 Aug 18;17(10):91. doi: 10.1007/s11892-017-0926-8.
8
First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
Drugs Today (Barc). 2015 Mar;51(3):185-96. doi: 10.1358/dot.2015.51.3.2294596.
9
GLP-1R agonist therapy for diabetes: benefits and potential risks.
Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):87-97. doi: 10.1097/MED.0b013e32835edb32.
10
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Postgrad Med. 2018 May;130(4):375-380. doi: 10.1080/00325481.2018.1450058. Epub 2018 Mar 20.
引用本文的文献
1
Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.
Diabetol Metab Syndr. 2025 May 16;17(1):156. doi: 10.1186/s13098-025-01722-8.
2
Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy.
Cureus. 2024 May 8;16(5):e59899. doi: 10.7759/cureus.59899. eCollection 2024 May.
3
Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a Glucagon-like Peptide-1 Agonist.
Fed Pract. 2024 Feb;41(2):52-56. doi: 10.12788/fp.0452. Epub 2024 Feb 14.
4
100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future.
Biomedicines. 2024 Feb 27;12(3):533. doi: 10.3390/biomedicines12030533.
5
Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment.
J Clin Med Res. 2023 Sep;15(8-9):406-414. doi: 10.14740/jocmr4995. Epub 2023 Sep 30.
6
Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.
Diabetol Metab Syndr. 2023 Aug 19;15(1):173. doi: 10.1186/s13098-023-01141-7.
7
The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy.
Medicine (Baltimore). 2023 Mar 10;102(10):e33167. doi: 10.1097/MD.0000000000033167.
8
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
BMC Endocr Disord. 2023 Feb 1;23(1):28. doi: 10.1186/s12902-023-01282-w.
9
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.
J Diabetes Sci Technol. 2024 May;18(3):653-659. doi: 10.1177/19322968221149041. Epub 2023 Jan 29.
10
Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis.
Cell Rep. 2022 Nov 22;41(8):111698. doi: 10.1016/j.celrep.2022.111698.
本文引用的文献
1
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252.
2
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Diabetes Obes Metab. 2016 Jan;18(1):40-8. doi: 10.1111/dom.12574. Epub 2015 Nov 5.
3
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1.
4
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Diabetes Care. 2015 Jul;38(7):1263-73. doi: 10.2337/dc14-1984. Epub 2015 Apr 17.
5
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.
6
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016/S0140-6736(14)61335-0. Epub 2014 Sep 11.
7
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.
8
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Diabetes Care. 2014 Nov;37(11):2926-33. doi: 10.2337/dc14-0785. Epub 2014 Aug 11.
9
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.
10
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Diabetes Care. 2014 Aug;37(8):2317-25. doi: 10.2337/dc14-0001. Epub 2014 Jun 4.
Zotero 插件